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Objective To evaluate the diagnostic performance of an enzyme immunosorbent assay (recomWell
Treponema) for the diagnosis of syphilis. The novel recombinant antigens Tpn47, TpN17 and TpN15 were
utilized.
Methods A total of 782 human serum specimens, belonging to four different categories (blood donors,
n ¼ 200; routine laboratory screening for syphilis, n ¼ 400; syphilis patients, n ¼ 122; potential cross-reactors,
n ¼ 60), were evaluated to compare the sensitivity and specificity of the recomWell Treponema kit with a
standard whole Treponema pallidum cell lysate antigen-based ELISA (Syphilis Screening) and with micro-
haemagglutination (MHA-TP).
Results The overall specificity and sensitivity of the recomWell Treponema IgG was 98.9% and 98.3%,
respectively. The specificity and sensitivity of Syphilis Screening ELISA was 98.7% and 98.3%, respectively. The
agreement between recomWell Treponema and Syphilis Screening was 100%, 97.8%, 95.9% and 95% among the
blood donor specimens, screening samples, syphilis specimens and the potential cross-reactors, respectively.
Values of concordance varying from 96.7% to 98.3% were found in the different groups of sera between
recomWell Treponema and MHA-TP. In addition, recomWell Treponema demonstrated a good diagnostic
performance when used to detect the IgM to T. pallidum. No false-positive sera were identified and, in 17/19
samples from primary infection, an IgM immune response was found.
Conclusions recomWell Treponema was shown to be a highly specific and sensitive method in all stages of
syphilis screening and it can be considered as alternative to other ELISA tests based on native antigen preparations.
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INTRODUCTION
The serologic diagnosis of syphilis has for many years been
carried out mainly with a two-step approach [1]. First,
serum samples were screened with a flocculation assay
using non-treponemal antigens to detect antibodies to
cardiolipin (Venereal Disease Research Laboratory [VDRL]
and rapid plasma reagin [RPR] test) and then, sera reactive
in the screening tests were evaluated again to identify spec-
ific antibodies to Treponema pallidum antigens [2] (trepone-
mal haemagglutination assay [MHA-TP] or fluorescent
treponemal antibody absorption test [FTA-ABS]). Since there
were limitations of the non-treponemal serologic tests [3]
(i.e. their lack of sensitivity in early dark-field positive primary
cases and in late syphilis, and the relatively high incidence of
false-positive reactions), the quest for a specific serologic
test for syphilis began many years ago and still continues.
The use of the immunoenzymatic techniques in the serology
of syphilis started in the mid 1970s [4] and, at present,
many different enzyme-linked immunosorbent assays (ELISAs)
are available and their usefulness as syphilis screening and
diagnosis methods has been proved extensively. The sensitivity
and specificity is comparable to treponemal tests like the
MHA-TP and FTA-ABS, but as in these traditional tests, the
sensitivity of ELISA is suboptimal in primary and congenital
disease [5–10]. This report assesses the diagnostic performance
(specificity and sensitivity) of a novel recombinant antigen-
based ELISA (recomWell Treponema, Mikrogen, Martinsried,
Germany) in comparison with a native antigen-based
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ELISA method (Syphilis Screening ELISA, Radim, Rome,
Italy) and with MHA-TP (Fujirebio, Tokyo, Japan). The
selection of syphilis sera to be evaluated was made by
clinical and laboratory criteria proposed by Norris and Larsen
[11].
MATERIALS AND METHODS
Study groups
This study involved a total of 782 human serum specimens. Two
hundred sera were obtained from the blood bank of the St
Orsola Hospital in Bologna, Italy; 400 sera were unselected
samples submitted to the Microbiology Laboratory of the St
Orsola Hospital for routine laboratory syphilis screening; 122
sera were obtained from patients attending the STD outpatient
clinic of the University of Bologna and suffering from syphilis at
various stages. In detail, eight sera were obtained from patients
with a clinical diagnosis of suspected primary syphilis with only
genital ulcer resembling the typical chancre but negative at the
direct fluorescent assay (DFA) of the lesion fluid (suspected
syphilis patients); 19 sera were obtained from patients with a
clinical- and laboratory-confirmed diagnosis of primary syphi-
lis; 24 sera were from patients with a clinical diagnosis of
secondary syphilis; 67 sera were from patients with a diagnosis
of latent syphilis; and four sera were from patients suffering from
late syphilis. The clinical and laboratory criteria proposed
by Norris and Larsen [11] have been followed to obtain the
T. pallidum infection status of each individual patient.
Furthermore, a panel of 60 sera was obtained from patients
suffering from some of the most common biological conditions
known as possibly giving a false-positive reactivity in syphilis
serology, such as serum specimens obtained from culture-con-
firmed Lyme disease patients [12–14] (n ¼ 20) and from lepto-
spirosis patients [15] (n ¼ 10, kindly provided by M. A. Santos,
INSA, Porto, Portugal), sera in which the presence of anti-
nuclear antibodies has been detected [16,17] (n ¼ 11, a gift of F.
Cassani, Bologna, Italy), serum samples drawn from subjects
with clinical diagnosis of infectious mononucleosis (showing a
positive Paul–Bunnel–Davidsohn reaction; n ¼ 10) and, finally,
sera from healthy, pregnant women (n ¼ 9).
RecomWellTreponema IgG and recomWellTreponema IgM testing
The recomWell Treponema test (Mikrogen, Martinsried,
Germany) is a quantitative in vitro method for the detection
of IgG or IgM antibodies against T. pallidum in human serum or
plasma samples. This test, prepared with recombinant form of
the T. pallidum antigens TpN47, TpN17 and TpN15, is based
on the principle of an indirect ‘sandwich’ enzyme immunoassay.
Briefly, serum samples, positive and negative controls, and cut-
off samples were diluted 1 : 101 in diluting buffer and 100 mL of
the diluted sera were pipetted in each well. Following incuba-
tion at 37 8C for 1 h, the wells were washed four times with a
solution containing 0.05% (v/v) Tween-20 in phosphate-
buffered saline (PBS; pH 7.0) and then 100 mL of anti-human
IgG (or IgM) horseradish peroxidase-conjugated antibody
solution (1 : 101 diluted in dilution buffer) were added to
each well. The plate was incubated at 37 8C for 30 min
and an additional washing cycle was performed. At the end,
100 mL of tetramethylbenzidine substrate solution were
pipetted in each well; after 30 min incubation at room tem-
perature the enzymatic reaction was stopped by adding 100 mL
of stop solution to each well. The results were read at 450 nm
after subtraction of the optical density (OD) values obtained at
the reference wavelength of 650 nm. The gray zone (i.e. the
range of values that cannot be considered as truly negative or
positive) was calculated as follows: the lower limit corresponded
to the OD value shown by the cut-off reference serum available
in the kit and the upper limit corresponded to the OD cut-off
value þ20%. Samples with OD values above the gray range
were considered positive; samples with OD values below the
gray range were considered negative. Samples showing an OD
value falling in the gray range were boundary cases and, follow-
ing the manufacturer’s instructions, they were tested again.
Syphilis Screening ELISA test
This is an enzyme immunoassay intended for the detection of
total human immunoglobulins to a T. pallidum whole-cell native
preparation. In detail, T. pallidum spp. pallidum (Nichols strain)
was grown in testes of male New Zealand white rabbits for
10–14 days. At the end of this period the animals were eutha-
nasized, the testes were spliced and resuspended in PBS
(pH 7.2). The spirochetes were extracted from this tissue with
gentle rotation under anaerobic atmosphere. The bacterial
suspension was then washed once and the microrganisms were
sonicated to disrupt the bacterial bodies. The obtained mixture
of treponemal antigens was used to coat ELISA plates, following
a standard procedure. This kit is based on a conventional
competitive ELISA method that is capable of detecting the
total Ig immune response to T. pallidum in human serum
specimens [9,18–20].
Testing was performed following the manufacturer’s instruc-
tions and all the specimens showing an equivocal result were
tested twice.
MHA-TP
All the 782 samples were subjected to confirmatory testing by a
quantitative MHA-TP method (Fujirebio, Tokyo, Japan). The
MHA-TP was performed in accordance to the manufacturer’s
instructions, which had an established cut-off value correspond-
ing to a 1 : 80 dilution.
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RESULTS
IgG findings
Blood donor serum specimens
Preliminary experiments were made by testing 200 sera
obtained from the St Orsola Hospital blood bank with recom-
Well Treponema IgG to assess the specifity of this new ELISA
test; all the sera were also tested by Syphilis Screening ELISA
and MHA-TP. No sample showed either a positive or equivocal
result when tested by any technique, so the specificity of all the
methods was 100% when applied to this group of sera. Con-
sequently, the values of agreement between all these methods
were 100% (Tables 1 and 2).
Sera submitted for routine laboratory screening
for syphilis
Thirteen samples out of this group of 400 sera were posit-
ive when tested by recomWell Treponema IgG. (Table 3
reports details for discrepant results found among this group
of specimens). The agreement between recomWell Treponema
IgG and Syphilis Screening ELISA was 97.8% (Table 1).
The sensitivity, specificity and agreement values obtained
by comparing recomWell Treponema IgG to MHA-TP
were 100%, 98.3% and 98.3%, respectively (see Table 2 for
details).
Syphilis specimens
A total of 112 out of 122 samples were reactive when tested by
recomWell Treponema IgG: of the 10 negative sera, eight were
from patients with clinically suspected primary syphilis and two
from patients showing a positive DFA slide with clinically
confirmed primary syphilis. No negative result was obtained
by the different tests used when sera from secondary, latent or
late syphilis was studied. Detailed results for sera showing
discrepant results are given in Table 3.
The agreement between recomWell Treponema IgG and
Syphilis Screening ELISA was 95.9% (Table 1). The perfor-
mances of recomWell Treponema IgG compared to MHA-
TP gave sensitivity and specificity values of 98.2% and
88.9%, respectively, whereas the agreement was 97.5%
(Table 2).
Table 1 Comparison of recomWellTreponema IgG and Syphilis Screening ELISA reactivities with syphilis specimens, healthy blood donor specimens, cross-
reacting specimens and screening samples
Specimen category No.tested þ and þ þ and ^ ^ and þ ^ and ^ % Agreement
Syphilis 122 110 2 3 7 95.9%
Suspected syphilis 8 0 0 2 6 75%
Primary syphilis 19 15 2 1 1 84.2%
Secondary syphilis 24 24 0 0 0 100%
Early latent syphilis 67 67 0 0 0 100%
Late syphilis 4 4 0 0 0 100%
Blood donors 200 0 0 0 200 100%
Cross-reacting 60 1 1 2 56 95%
Screening samples 400 8 5 4 383 97.8%
The results obtained for sera drawn from different stages of syphilis are in italics.
Table 2 Comparison of recomWell Treponema IgG and MHA-TP reactivities with syphilis specimens, healthy blood donor specimens, cross-reacting speci-
mens and screening samples
Specimen category No.tested þ and þ þ and ^ ^ and þ ^ and ^ % Agreement
Syphilis 122 111 1 2 8 97.5%
Suspected syphilis 8 0 0 1 7 87.5%
Primary syphilis 19 16 1 1 1 89.4%
Secondary syphilis 24 24 0 0 0 100%
Early latent syphilis 67 67 0 0 0 100%
Late syphilis 4 4 0 0 0 100%
Blood donors 200 0 0 0 200 100%
Cross-reacting 60 0 2 0 58 96.7%
Screening samples 400 6 7 0 387 98.3%
The results obtained for sera drawn from different stages of syphilis are in italics.
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Cross-reacting samples
Two out of the 60 samples belonging to the cross-reacting
panel were reactive when tested by recomWell Treponema
IgG: one was obtained from a Lyme disease patient and the
second from a patient suffering from infectious mononucleosis.
Table 3 shows detailed results. No positive reaction was
obtained when these sera were tested by MHA-TP. The
specificity of recomWell Treponema IgG in this group of sera
was 96.7%. The same value was detected for the agreement
between this immunoenzymatic method and MHA-TP
(Table 2). Syphilis Screening ELISA performed with a speci-
ficity of 95%, whereas MHA-TP was shown to be 100%
specific. The comparison between the two immunoenzymatic
tests showed an agreement of 95%.
IgM findings
Blood donor serum specimens and cross-reacting
samples
No sample belonging to these two groups of sera showed
equivocal or positive result when tested by recomWell
Treponema IgM.
Sera submitted for routine laboratory screening
for syphilis
Six out the 13 sera positive by recomWell Treponema IgG were
also positive by recomWell Treponema IgM. Moreover, two out
of the 12 sera positive by Syphilis Screening ELISA and negative
by the other tests were also positive or equivocal by recomWell
Treponema IgM. When tested by MHA-TP, these sera were
scored negative.
Syphilis specimens
The 17 sera from primary syphilis that were identified as
positive by recomWell Treponema IgG, also gave positive results
when analyzed by recomWell Treponema IgM. All these
samples were also positive by Syphilis Screening ELISA. No
specimen obtained from patients suffering from later sy-
philis stages gave positive result when tested by recomWell
Treponema IgM.
DISCUSSION
The diagnosis of syphilis is based upon clinical symptoms and
laboratory results [1,17]. As the lesion material is only available
for direct examination during the early disease, the main
laboratory diagnostic tool for stages later than primary syphilis
is serology [21]. Recently, several different preparations of
recombinant T. pallidum antigens have been described [22–25]
and their diagnostic performance by ELISA for syphilis has
been assessed [26,27]. In this study, the performance of recom-
Well Treponema, a novel ELISA kit containing a recombinant
form of three T. pallidum antigens was evaluated. recomWell
Treponema is based on the identification of the Ig response to
the following recombinant polypeptides: TpN47, TpN17 and
TpN15. This test is designed for the identification of a specific
IgG (recomWell Treponema IgG) or IgM (recomWell Trepo-
nema IgM) immune response in syphilis. In this study the
Table 3 Detailed results for sera from previous tables with discrepant results
Sample no. Specimen category recomWell IgG Syphilis Screening ELISA MHA-TP (titer)
202 Suspected syphilis Negative Positive Negative
208 Suspected syphilis Negative Positive 80
215 Primary syphilis Negative Positive 80
220 Primary syphilis Positive Negative Negative
224 Primary syphilis Positive Negative 160
390 Screening sample Positive Negative Negative
410 Screening sample Positive Negative Negative
527 Screening sample Positive Negative Negative
654 Screening sample Positive Negative Negative
703 Screening sample Positive Negative Negative
544 Screening sample Negative Positive Negative
599 Screening sample Negative Positive Negative
631 Screening sample Negative Positive Negative
706 Screening sample Negative Equivocal Negative
387 Screening sample Positive Positive Negative
479 Screening sample Positive Positive Negative
735 Cross-reacting Positive Positive Negative
770 Cross-reacting Positive Negative Negative
761 Cross-reacting Negative Positive Negative
780 Cross-reacting Negative Positive Negative
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overall diagnostic performance of this method was compared to
the routinely used immunoenzymatic assay in our laboratory,
Syphilis Screening ELISA, and to a non-ELISA confirmatory
method, such as MHA-TP. A first evaluation, made on 200 sera
obtained from the blood bank of the St Orsola Hospital, showed
that recomWell Treponema IgG and recomWell Treponema
IgM are specific methods, since none of these samples was
identified as positive by either IgG or IgM evaluation. When
applied to a panel of 60 potential cross-reacting sera, recomWell
Treponema IgG performed with a specificity of 96.6%. This loss
of specificity was due to a sample from a Lyme disease patient
and to another sample from a patient suffering from infectious
mononucleosis, positive by this immunoassay. recomWell Tre-
ponema IgM was shown to be 100% specific also in this group of
specimens, since no sample gave a positive result. The specificity
and sensitivity of Syphilis Screening ELISA were 98.7% and
98.3%, respectively. A good advantage of recomWell Trepo-
nema, compared to Syphilis Screening ELISA, is the possibility
to discriminate between two different classes of immunoglo-
bulins (IgG and IgM). The identification of the IgM immune
response is generally considered not useful in the diagnostic
procedure of sexually acquired syphilis, whereas the detection
of this antibody subclass has been proved an important adjunc-
tive tool in the laboratory investigation of congenital T. pallidum
infection [11,28,29]. recomWell Treponema IgM could prob-
ably also be useful in this case, as suggested by the specificity and
sensitivity shown in the present study. When applied to sera
drawn from primary syphilis patients, recomWell Treponema
IgM was shown to be able to identify a specific IgM immune
response in 17/19 sera (89.5%). This loss of sensitivity of the
ELISA method when applied to sera from primary syphilis is as
expected, since all the diagnostic tests have suboptimal sensi-
tivity when applied to primary syphilis patients.
The decrease of sensitivity is well explained by the criteria
followed to classify a result on a serum as indicating early
infection [11]: only in the case of a positive DFA slide could
a patient be diagnosed as suffering from primary syphilis.
Lacking this laboratory confirmation, only the diagnosis of
suspected primary syphilis must be posed, resulting in a well
known bias in the criteria for the selection of this group of
specimens. The detection of an immune response is the most
widely used method in the laboratory diagnosis of syphilis both
for the identification of patients suspected to be suffering from
secondary, latent and late syphilis, and for epidemiological
purposes [1,3,11]. Quite recently, several native [7–10] or
recombinant [22–24,26,27], antigen ELISA methods for the
detection of antibody response to T. pallidum have been eval-
uated, and their overall sensitivity and specificity have been
comparable to those of MHA-TP. In this study we showed that
recomWell Treponema is a highly specific and sensitive method,
capable of detecting IgG and IgM antibodies in human serum in
all stages of syphilis, and it can be considered a good alternative
to the other ELISA tests based on native T. pallidum antigen
preparations. These advantages are principally due to the fact
that the availability of recombinant antigens is not connected to
the growth of treponemes in animals. Consequently, the diag-
nostic use of these polypetides can overcome the well known
problem of keeping constant over time the antigenic properties
of animal-derived T. pallidum proteins. In addition, large quan-
tities of recombinant antigens can be produced in quite a simple
way, contributing to lower costs for this new test.
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